To the Editor The review by Dr Kohli and colleagues1 illustrated how hepatitis C virus (HCV) treatment has moved from the low efficacy and high complication rates observed with ribavirin plus interferon to the high sustained viral response (SVR) and rare complication rates observed with directly acting antivirals. Directly acting antivirals have been embraced by clinical guidelines2 and, given their comparable safety and efficacy, the discussion over which specific drug will be used in the near future has turned to availability and affordability. Yet in the midst of this discussion is a more clinically relevant question: now that SVR and safety seem assured, should the outcomes of HCV treatment be redefined?
Chavez-Tapia NC, Barrientos-Gutierrez T, Uribe M. Assessment of Outcomes of Hepatitis C Treatment. JAMA. 2014;312(23):2570-2571. doi:10.1001/jama.2014.14900